The DBN1 antibody is a specific immunoglobulin designed to detect Drebrin 1 (DBN1), an actin-binding protein encoded by the DBN1 gene on human chromosome 5q35.3. This protein plays critical roles in neuronal development, synaptic plasticity, and immune cell function . The antibody is widely used in research to study DBN1 expression in diseases such as Alzheimer’s disease, breast cancer, and viral infections .
Target: Drebrin 1 (DBN1), an actin-binding protein with isoforms Drebrin A (neuronal) and Drebrin E (non-neuronal) .
Applications: Western blotting (WB), immunohistochemistry (IHC), immunofluorescence (IF), and immunoprecipitation (IP) .
Species Reactivity: Primarily human, with cross-reactivity in mouse and rat .
DBN1 expression has been identified as a prognostic marker in luminal breast cancer. High DBN1 levels correlate with aggressive tumor characteristics and poor response to endocrine therapy . Studies using DBN1 antibodies (e.g., Abcam ab268046) demonstrated that elevated DBN1 predicts recurrence and metastasis in treated patients .
In dendritic cells, DBN1 regulates antigen presentation and T-cell activation by stabilizing actin filaments . Antibodies like Cell Signaling’s 96540 revealed impaired phagocytosis and reduced surface receptor expression in DBN1-silenced cells .
DBN1 inhibits dynamin-mediated endocytosis, restricting rotavirus and other viral entries. Antibodies (e.g., Proteintech 10260-1-AP) confirmed DBN1’s interaction with cortactin at actin filaments, critical for this antiviral mechanism .
Circulating DBN1 levels correlate with retinal ganglion cell injury in glaucoma patients, suggesting its potential as a biomarker for disease severity .